Epigenomics AG Gives Detailed Account of Research into Optimized Assay Procedure for Early Cancer Detection at CHI’s G.O.T. Summit

Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, yesterday presented research geared at developing a generic workflow for testing its proprietary DNA methylation biomarkers for the early detection of various types of cancer in blood plasma at the Cambridge Healthtech Institute’s G.O.T. Summit in Boston, MA, U.S.A..